bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On December 1, 2016, bluebird bio, Inc. (bluebird) will be
conducting an investor webcast summarizing clinical data from its
anti-BCMA CAR T cell therapy, being presented at the
EORTC-NCI-AACR Molecular Targets and Cancer Therapies Symposium
on December 1, 2016. A copy of the presentation is being
furnished as Exhibit 99.2 to this Report on Form 8-K. The
information in Item 7.01 of this Report on Form 8-K and Exhibit
99.2 attached hereto is intended to be furnished and shall not be
deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such filing.
Item 8.01Other Events
On November 30, 2016, bluebird bio, Inc. issued a press release
announcing clinical data from its anti-BCMA CAR T cell therapy,
being presented at the EORTC-NCI-AACR Molecular Targets and
Cancer Therapies Symposium on December 1, 2016. The full text of
the press release regarding the announcement is filed as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
|
99.1 99.2 |
Press release issued by bluebird bio, Inc. on November
Investor presentation provided by bluebird bio, Inc. on |
|
About bluebird bio, Inc. (NASDAQ:BLUE)
bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline. bluebird bio, Inc. (NASDAQ:BLUE) Recent Trading Information
bluebird bio, Inc. (NASDAQ:BLUE) closed its last trading session down -4.05 at 60.35 with 2,047,052 shares trading hands.